Eli Lilly and Company is unveiling its new 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, which will be available ...

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Tom Dorsett, CEO, RazorMetrics, comments on why he believes polypharmacy is an overlooked driver of unnecessary ...

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Tom Dorsett, CEO, RazorMetrics, ...

Selarsdi is approved by the FDA in several presentations, including 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled ...

In the third part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Laura Johnson, senior director of ...

FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.

Leaders with top third-party logistics providers discuss the evolving landscape for the sector in 2025—and the new strides made in their quest to help transform the pharma supply chain. Third-party ...

In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, describes why these pharma supply chain stakeholders are ...

In the fourth part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, explains the value of FDA guidance documents for ...

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jim Shehan, chair of the FDA regulatory practice at Lowenstein Sandler, explains how he anticipates the evolving ...

Welcome to the second installment of the “Popping the Gross-to-Net Bubble” series. In this column, I’ll dive into actionable steps pharmaceutical manufacturers can take to address this issue. This ...